Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure (PH-HF)
Post-capillary Pulmonary Hypertension
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure.|
- Prognostic [ Time Frame: 2 years ]Estimate the prognosis of different forms of HTPcap in heart failure (ejection fraction altered, stored or valvular heart disease)
- Prevalence [ Time Frame: 3 years ]Define the prevalence of different forms of active or passive HTPcap
- Phenotype [ Time Frame: 3 years ]Define the phenotypic characteristics of patients with reactive or passive HTPcap in heart failure
Biospecimen Retention: Samples With DNA
- 3 tubes of 6 blood for analysis of biomarkers
- 2 tubes of 6 mL blood for DNA analysis
|Study Start Date:||February 2012|
|Estimated Study Completion Date:||December 2018|
|Estimated Primary Completion Date:||July 2018 (Final data collection date for primary outcome measure)|
HTPcap in IC
HTPcap active and passive in a population of stable patients with heart failure (left ventricular ejection fraction impaired or preserved) and / or valvular disease who received a left right heart catheterization as part of their care.
Patients with heart failure (HF) frequently have a post-capillary pulmonary hypertension (HTPcap) which has two forms: passive and reactive.
The prognosis, prevalence and pathophysiological mechanisms of cell and tissue involved in the onset and reversibility of these two forms of HTPcap remain poorly understood.
The latest recommendations of the European Society of Cardiology and the European Respiratory Society identify two forms of HTPcap in the IC as a function of the extent of trans-pulmonary gradient (GTP) measured during right heart catheterization (GTP = mPAP-Pcap): passive (GTP £ 12mmHg) and reactive (GTP> 12mmHg).
In the latter form, the increase in pulmonary pressure would be disproportionate to the increase in left ventricular pressures.
This study will permit to identify hemodynamic prognostic markers of the the IC, and clinical, biological and hemodynamic determinants of the HTPcap in the IC.
This will help to identify a population that could benefit from specific treatment to referred pulmonary artery.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01545180
|Contact: Tibaud DAMY||33(0)email@example.com|
|Contact: Genevieve Mulak||33(0)firstname.lastname@example.org|
|Henri Mondor Hospital||Recruiting|
|Creteil, France, 94000|
|Contact: Thibaud DAMY 33(0)144907028 email@example.com|
|Contact: Geneviève Mulak 33(0)143223333 firstname.lastname@example.org|
|Principal Investigator: Thibaud DAMY|
|Principal Investigator:||Thibaud DAMY||Assistance Publique - Hôpitaux de Paris|